BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Crry gene therapy to treat multiple sclerosis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Adeno-associated viral vector (AAV)-mediated overexpression of the complement inhibitor Crry at C3-bound synapses could treat MS. The AAV9 vector encodes Crry fused to a domain of CR2,...
BC Extra | Jan 18, 2020
Financial News

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Shares of I-Mab slipped 11% in their first day of trading Friday after the Shanghai-based company priced its IPO on NASDAQ within its proposed range, raising $104 million to fund its cross-border development strategy. The...
BC Extra | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

ChemoCentryx became the latest biotech to post a triple-digit percentage gain based on a clinical readout, adding more than $1.3 billion in market cap after its avacopan showed statistical superiority to standard-of-care therapy in a...
BC Extra | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

GBT's sickle cell therapy snags accelerated approval  FDA granted accelerated approval to Oxbryta voxelotor from Global Blood Therapeutics Inc. (NASDAQ:GBT) to treat sickle cell disease three months ahead of its Feb. 26 PDUFA date, marking...
BC Extra | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BC Innovations | Aug 29, 2019
Distillery Therapeutics

Platelet transfusions for sepsis

DISEASE CATEGORY: Infectious disease INDICATION: Sepsis Platelet transfusions could treat sepsis by inducing monocytes to mature into proinflammatory macrophages. When co-cultured with platelets, activated monocytes were more likely to differentiate to M1 macrophages with proinflammatory...
BC Innovations | Jul 18, 2019
Distillery Therapeutics

Gossamer's CR3 agonist sensitizes pancreatic cancer to therapies

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Gossamer Bio Inc.'s CR3 agonist, GB1275, could sensitize pancreatic cancer to chemotherapy, radiation and immunotherapy. A team co-led by Rush University's Vineet Gupta, who co-founded Gossamer-acquired Adhaere Pharmaceuticals Inc.,...
BC Extra | Jun 5, 2019
Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

After reporting a high clinical response rate in a Phase IIa study, InflaRx lost $34.28 (92%) to $3.01 in afternoon trading Wednesday after all doses of IFX-1 failed to meet the primary endpoint in the...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
Items per page:
1 - 10 of 180